Tangerang City

Researchers are evaluating whether the medicine tenecteplase helps adults recover from an acute ischemic stroke when given more than 4.5 hours after they were last seen well. This study focuses on people who had a stroke caused by a clot blocking blood flow in the brain and who have imaging showing brain tissue that can still be saved. Participants should not be planning to receive a procedure to remove the clot and must have a pre-stroke disability level of 0 or 1 on the modified Rankin Scale. Participants are randomly placed into two groups. One group receives a single injection of tenecteplase into a vein, while the other group receives standard medical care. The study includes adults aged 18 and over who had an acute stroke or woke up with stroke symptoms more than 4.5 hours ago. Imaging with MRI or CT is used to confirm eligibility. The study lasts about three months, starting with a hospital stay of about one week. During the study, participants have seven clinical examinations or visits to monitor their recovery and health. The last two visits may be done from home to allow remote assessments. Researchers use the modified Rankin Scale to measure disability or dependence in daily activities at 90 days after treatment. They also monitor for any side effects or health changes to compare the effects of tenecteplase against standard care.

Researchers are evaluating the effectiveness, safety, and tolerability of adding metformin to the standard multi-drug therapy (MDT) for patients newly diagnosed with multibacillary leprosy. This double-blind, placebo-controlled Phase 2 trial aims to see if metformin can reduce leprosy reactions, nerve damage, and the need for corticosteroids, while also exploring its effects on immune system markers. The study plans to enroll 166 patients aged 18 to 65 years from leprosy endemic areas in Indonesia. Participants will be randomly assigned to receive either metformin 1000 mg once daily or a placebo for 24 weeks, alongside the standard MDT which continues for 48 weeks. The study compares these two groups to assess how metformin as an additional treatment might influence clinical outcomes. This trial is funded by the Leprosy Research Initiative and follows strict protocols to ensure reliable results. During the 48-week study period, participants will be monitored for leprosy reactions and adverse events, with primary outcomes focused on the proportion experiencing these reactions and side effects. Secondary measures include severity and timing of reactions, the amount of corticosteroids used, and quality of life assessments. Regular evaluations include clinical examinations and safety checks to track the participants' health and treatment adherence throughout the study.